• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过化学相似性搜索进行先导物验证和构效关系研究;应用于靶向p56lck的SH2结构域pY+3位点的化合物

Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.

作者信息

Macias Alba T, Mia Md Younus, Xia Guanjun, Hayashi Jun, MacKerell Alexander D

机构信息

Department of Pharmaceutical Sciences, University of Maryland, 20 Penn Street, Baltimore, Maryland 21201, USA.

出版信息

J Chem Inf Model. 2005 Nov-Dec;45(6):1759-66. doi: 10.1021/ci050225z.

DOI:10.1021/ci050225z
PMID:16309282
Abstract

Compound selection based on chemical similarity has been used to validate active "parent" compounds identified via database searching as viable lead compounds and to obtain initial structure-activity relationships for those leads. Twelve parent compounds that have inhibitory activity against the SH2 domain of the p56 T-cell tyrosine kinase (Lck) are the focus of this study. Lck is involved in the T-cell mediated immune response, and inhibitors of Lck protein-protein interactions could potentially be used to develop novel immunosuppressants. Similarity searches for each parent compound were performed using 2D structural fingerprints on a database containing 1,300,000 commercially available compounds. The inhibitory activity of the selected compounds was assessed using enzyme immunoassay (EIA). In general, the most active parent compounds yield the most high activity similar compounds; however, in two cases low activity parent compounds (i.e. inhibitory activity < 25% at 100 microM) yielded multiple similar compounds with activities > 60%. Such compounds may, therefore, be considered as viable lead compounds for optimization. Structure-activity relationships were explored by examining both ligand structures and their computed bound conformations to the protein. Functional groups common to the active compounds as well as key amino acid residues that form hydrogen bonds with the active compounds were identified. This information will act as the basis for the rational optimization of the lead compounds.

摘要

基于化学相似性的化合物筛选已被用于验证通过数据库搜索确定的具有活性的“母体”化合物作为可行的先导化合物,并获得这些先导化合物的初始构效关系。本研究聚焦于12种对p56 T细胞酪氨酸激酶(Lck)的SH2结构域具有抑制活性的母体化合物。Lck参与T细胞介导的免疫反应,Lck蛋白-蛋白相互作用的抑制剂有可能被用于开发新型免疫抑制剂。使用二维结构指纹图谱在一个包含130万种市售化合物的数据库中对每种母体化合物进行相似性搜索。使用酶免疫测定(EIA)评估所选化合物的抑制活性。一般来说,活性最高的母体化合物会产生最多的高活性相似化合物;然而,在两个案例中,低活性母体化合物(即在100 microM时抑制活性<25%)产生了多种活性>60%的相似化合物。因此,这类化合物可被视为优化的可行先导化合物。通过检查配体结构及其与蛋白质计算得出的结合构象来探索构效关系。确定了活性化合物共有的官能团以及与活性化合物形成氢键的关键氨基酸残基。这些信息将作为先导化合物合理优化的基础。

相似文献

1
Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.通过化学相似性搜索进行先导物验证和构效关系研究;应用于靶向p56lck的SH2结构域pY+3位点的化合物
J Chem Inf Model. 2005 Nov-Dec;45(6):1759-66. doi: 10.1021/ci050225z.
2
Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.通过针对pY + 3结合位点的计算机模拟筛选,鉴定酪氨酸激酶p56 Lck SH2结构域的不含磷酸盐的小分子抑制剂。
J Med Chem. 2004 Jul 1;47(14):3502-11. doi: 10.1021/jm030470e.
3
Phosphotyrosine-containing dipeptides as high-affinity ligands for the p56lck SH2 domain.含磷酸酪氨酸的二肽作为p56lck SH2结构域的高亲和力配体。
J Med Chem. 1999 Feb 25;42(4):722-9. doi: 10.1021/jm980612i.
4
SVM model for virtual screening of Lck inhibitors.用于Lck抑制剂虚拟筛选的支持向量机模型
J Chem Inf Model. 2009 Apr;49(4):877-85. doi: 10.1021/ci800387z.
5
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.一类新型强效选择性三取代嘌呤类化合物抑制Src酪氨酸激酶的结构基础
Chem Biol Drug Des. 2006 Jan;67(1):46-57. doi: 10.1111/j.1747-0285.2005.00316.x.
6
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.基于结构设计新型2-氨基-6-苯基-嘧啶并[5',4':5,6]嘧啶并[1,2-a]苯并咪唑-5(6H)-酮作为淋巴细胞特异性激酶(Lck)的强效口服活性抑制剂:合成、构效关系及体内抗炎活性
J Med Chem. 2008 Mar 27;51(6):1637-48. doi: 10.1021/jm701095m. Epub 2008 Feb 16.
7
Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements.酪氨酸激酶p56lck SH2结构域的配体:具有单电荷、不可水解磷酸替代物的高效二肽衍生物的发现。
J Med Chem. 1999 May 20;42(10):1757-66. doi: 10.1021/jm980676t.
8
Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.新型2-氨基嘧啶氨基甲酸盐作为Lck的强效口服活性抑制剂:合成、构效关系及体内抗炎活性
J Med Chem. 2006 Aug 10;49(16):4981-91. doi: 10.1021/jm060435i.
9
The importance of CH/pi hydrogen bonds in rational drug design: An ab initio fragment molecular orbital study to leukocyte-specific protein tyrosine (LCK) kinase.碳氢/π氢键在合理药物设计中的重要性:针对白细胞特异性蛋白酪氨酸(LCK)激酶的从头算片段分子轨道研究。
Bioorg Med Chem. 2008 Dec 15;16(24):10311-8. doi: 10.1016/j.bmc.2008.10.041. Epub 2008 Oct 22.
10
Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.新型强效且具选择性的基于底物的p60c-src蛋白酪氨酸激酶抑制剂系列的发现:肽设计中的构象和拓扑限制
J Med Chem. 1998 Jun 18;41(13):2252-60. doi: 10.1021/jm9707885.

引用本文的文献

1
Discovery of beta-lactamase CMY-10 inhibitors for combination therapy against multi-drug resistant Enterobacteriaceae.发现β-内酰胺酶 CMY-10 抑制剂用于联合治疗多药耐药肠杆菌科。
PLoS One. 2021 Jan 15;16(1):e0244967. doi: 10.1371/journal.pone.0244967. eCollection 2021.
2
Computer-Aided Drug Design Methods.计算机辅助药物设计方法
Methods Mol Biol. 2017;1520:85-106. doi: 10.1007/978-1-4939-6634-9_5.
3
The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis.小分子IMR-1抑制Notch转录激活复合物以抑制肿瘤发生。
Cancer Res. 2016 Jun 15;76(12):3593-603. doi: 10.1158/0008-5472.CAN-16-0061. Epub 2016 Apr 13.
4
Structure-activity exploration of a small-molecule Lipid II inhibitor.一种小分子脂磷壁酸前体抑制剂的构效关系探索
Drug Des Devel Ther. 2015 Apr 24;9:2383-94. doi: 10.2147/DDDT.S79504. eCollection 2015.
5
Turning defense into offense: defensin mimetics as novel antibiotics targeting lipid II.化防御为进攻:防御素模拟物作为靶向脂磷壁酸的新型抗生素。
PLoS Pathog. 2013;9(11):e1003732. doi: 10.1371/journal.ppat.1003732. Epub 2013 Nov 7.
6
Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.靶向蛋白酪氨酸磷酸酶 SHP2 治疗 PTPN11 相关恶性肿瘤。
Mol Cancer Ther. 2013 Sep;12(9):1738-48. doi: 10.1158/1535-7163.MCT-13-0049-T. Epub 2013 Jul 3.
7
Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.(Z)-3-(2-氨乙基)-5-(4-乙氧基苯亚甲基)噻唑烷-2,4-二酮的结构修饰,提高了对含有活跃 ERK 信号的黑色素瘤细胞增殖的抑制选择性。
Org Biomol Chem. 2013 Jun 14;11(22):3706-32. doi: 10.1039/c3ob40199e.
8
Inhibition of protein-protein interactions with low molecular weight compounds.利用低分子量化合物抑制蛋白质-蛋白质相互作用。
Curr Trends Med Chem. 2008 Jan 1;5:21-32.
9
Computer applications for prediction of protein-protein interactions and rational drug design.用于预测蛋白质-蛋白质相互作用和合理药物设计的计算机应用程序。
Adv Appl Bioinform Chem. 2009;2:101-23. Epub 2009 Nov 10.
10
Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.SARS-3CLpro 抑制剂:虚拟筛选、生物评价和分子动力学模拟研究。
J Chem Inf Model. 2011 Jun 27;51(6):1376-92. doi: 10.1021/ci1004916. Epub 2011 May 23.